Daptomycin dosing in obese patients: analysis of the use of adjusted body weight actual body weight.

Background: Food and Drug Administration-approved daptomycin dosing uses actual body weight, despite limited dosing information for obese patients. Studies report alterations in daptomycin pharmacokinetics and creatine phosphokinase elevations associated with higher weight-based doses required for obese patients. Limited information regarding clinical outcomes with alternative daptomycin dosing strategies in obesity exists.

Clostridium difficile treatment in neutropenic patients: Clinical outcomes of metronidazole, vancomycin, combinations, and switch therapy.

Background: Clostridium difficile infection treatment guidelines exist for immunocompetent patients; however, there is a paucity of data evaluating clinical outcomes and time to C. difficile-associated diarrhea resolution in neutropenic patients.

Objective: To assess clinical outcomes in neutropenic patients treated with metronidazole, oral vancomycin, the combination of metronidazole plus oral vancomycin, and switch of metronidazole to oral vancomycin.

Zidovudine as modern day salvage therapy for HIV infection.

Resistance to the first-line NRTIs, tenofovir and emtricitabine, does not generally confer resistance to zidovudine. The objective of this study was to describe the efficacy of zidovudine as modern day salvage antiretroviral therapy. This was a single-center, retrospective, observational, cohort study.